oncology

News in brief: Targeted radioligand therapy in prostate cancer; Wider access to encorafenib for mCRC;  Risk assessment test will allow personalised treatment plans for DCIS

Targeted radioligand therapy promising in prostate cancer Radioligand therapy with Lutetium-177-PSMA-617 prolongs imaging-based survival when added to standard care in patients with advanced PSMA-positive metastatic castration-resistant prostate cancer. A open-label phase 3 trial of 831 PSMA-positive metastatic castration-resistant prostate cancer patients found PFS was 8.7 months with the radioligand therapy compared to 3.4 months with ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic